Increase With Pharmaceutical Manufacturing
As per Vantage Market Research, the global pharmaceutical manufacturing market is anticipated to reach a valuation of $863.6 billion by 2030, projecting a compound annual growth rate (CAGR) of 7.8% from 2023 to 2030. The market experienced growth, reaching $510.5 billion in 2022. The research report attributes this growth to factors such as heightened demand for pharmaceutical products, technological advancements, and an increase in the prevalence of chronic disorders.
Pharmaceutical Manufacturing Research
Pharmaceutical manufacturing encompasses various processes, including research and development, formulation, quality control testing, packaging, and distribution. Specialized facilities are essential, adhering to strict regulations and standards to ensure the safety and efficacy of the products. Maintaining high levels of quality control and regulatory compliance is paramount in guaranteeing the safe and effective production of drugs.
Key highlights from the report include:
– In terms of drug development type, the outsource segment accounted for more than 54.3% of the total revenue share in 2022.
– The segment of conventional drugs (small molecules) is projected to experience the highest market growth during the forecasted period based on molecule type.
– North America led the market in 2022, contributing 42.3% of the total revenue.
– The Asia Pacific region is expected to witness substantial market growth in the forecast period.
– A noteworthy aspect highlighted is in the generics sector, where cost-effective alternatives to branded counterparts are emphasized. Vantage Market Research points to the robust global demand for generics, particularly in countries like India, where generic drugs constitute 70-80% of the nation’s retail market.
Several factors influence spending on Research and Development (R&D):
Drug companies base their decisions on research and development (R&D) spending on three primary factors:
1. Anticipated lifetime global revenues from a new drug.
2. Expected costs associated with developing a new drug.
3. Policies and programs that impact the supply of and demand for prescription drugs.
Companies consider various factors when predicting a drug’s revenue stream, including projected prices in different global markets and the expected sales volume at those prices, taking into account potential users. The prices and sales volumes of existing drugs provide insights into consumers’ and insurance plans’ willingness to pay for drug treatments. Crucially, when setting the prices of a new drug, companies aim to maximize future revenues after deducting manufacturing and distribution costs, and the sunk R&D costs (expenses already incurred in drug development) do not influence pricing decisions.
Developing new drugs is a costly and uncertain process, with approximately 12 percent of drugs entering clinical trials ultimately gaining FDA approval. Estimates of average R&D costs per new drug range from less than $1 billion to over $2 billion, covering laboratory research, clinical trials, and costs related to unsuccessful drugs. The federal government plays a role in shaping R&D decisions in three ways:
1. Increasing demand for prescription drugs through subsidies and tax preferences.
2. Augmenting the supply of new drugs by funding basic biomedical research and providing tax incentives.
3. Influencing both demand and supply through policies such as recommendations for specific vaccines and regulatory measures affecting returns on drug R&D, thereby impacting the number of new drugs entering the market.
Conclusion
Achieving value for consumers and optimizing the supply chain network, the ultimate goal of supply chain management, necessitates the integration of both inter and intra-organizational processes. The competitiveness of a firm is closely tied to effective integrated management. Process integration involves coordinating activities and sharing resources and information to collaboratively manage the entire process . According to Chopra and Mendhl, the advantages of supply chain integration encompass reductions in safety stock and costs, increased flexibility, responsiveness, and quality enhancement, along with optimal resource utilization . Despite these benefits, achieving process integration can pose challenges related to organizational culture, infrastructure and facilities, and the willingness to embrace learning and adapt to changes. Therefore, this model serves as a foundational framework for configuring an efficient and effective supply chain system.